CME Presentations

Geographic Atrophy



CME Information

Global LogoPQH Logo

Geographic Atrophy Secondary to AMD: Opportunities and Hopes for Those Affected

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Macular Degeneration Foundation (AMDF).


This activity is supported by an educational grant from Apellis Pharmaceuticals, Inc.


Tuesday, June 21, 2022 from 1:00 – 2:00 pm EST.


The target audiences for the HCP activity are ophthalmologists, advanced specialty practitioners, and ophthalmology nurses. Secondary audiences will include optometrists, as they play a key role in educating patients on risk factors and referring them to ophthalmologists.


Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries, and geographic atrophy (GA) secondary to AMD is responsible for approximately 20% of all cases of legal blindness. Still, many underestimate the burden of GA, a progressive and irreversible condition with few effective treatments, on patients and caregivers.

To help eye-care clinicians prepare for a paradigm shift in the management of GA, join a distinguished panel of ophthalmology experts to review the challenges in evaluating AMD and GA progression, as well as opportunities to improve monitoring with new and emerging technologies. The panel will discuss the pathophysiology underlying AMD and GA and how addressing the complement pathways could provide a viable management strategy. Current data on emerging agents for GA secondary to AMD will also be reviewed.


After completing this activity, the participant should be better able to:
  • Summarize the negative consequences that GA secondary to AMD has on patients and caregivers and be more proactive in helping patients and caregivers maintain quality of life
  • Appraise new and emerging technologies to monitor progression of AMD and GA secondary to AMD
  • Summarize the role of complement activation in the progression of AMD and GA secondary to AMD
  • Assess the efficacy and safety of emerging treatment options targeting the complement pathway for GA secondary to AMD


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Rishi P. Singh, MD
Staff Physician, Cleveland Clinic Florida
Professor of Ophthalmology, Case Western Reserve University
President, Cleveland Clinic Martin Hospital
Consulting Fee: Apellis, Genentech, Roche, Novartis, Graybug, Gyroscope, Asclepix
David S. Boyer, MD
Sr. Partner
Retina-Vitreous Associates Medical Group
Consulting Fee: 4DMT, Achillion Pharma, Acucela, Adverum Biotech, Aerie, AiViva BIo, Alcon, Aldeyra Therap, ALimera Sciences, Alkahest Allegro, Allergan, Allgenesis, Alzheon, Amgen, AMydis, Annexon BIoscience, Apellis Pharma, Applied Genetic Tech Corp, AsclepiX Therap, Aviceda, B&L, Bayer, Biogen, Bionic Vision Tech, Biovisics medical, Boehringer-Ingelheim, Cell Care, Chengdu Kanghong Biotech, Ciana Therap, Clearside Bio, DTx Pharma, Eloxx Pharma, EyePoint Pharma, Gemini Therap, Genentech, Glaukos, Graybug Vision, jCyte, I2vision, Kala Pharma, Isarna Therap, IvericBio, Kriya Therap, Kyowa Kirin, Linage Cell, LumiThera, Nanoscope Therao, Novartis, Ocular Therap, Ocugen, Oculis, Ocuphire, OcuTerra, Ocutrx Vision, OPhthea, Optigo Bio, Oxurion, Palatin Tech, Ray Therap, Regeneron, RetinAI, Ripple Therap, Roche, Santen, Smilebiotek, StealthBio, Surrozen, Thea Labs, Vanotech Corp, Verseon Corp, VItranu, Vitro Bio, Viva Vision
Contracted Research: Alcon, Allergan, Genentech, Regeneron, Novartis, Pfizer
Stock Option Holder: Allegro, DIgiSIght

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Alissa Yost Nothing to disclose
Jill Adelman Nothing to disclose
Joseph Adelman Nothing to disclose
Elizabeth Tully Consulting Fee: Roche Canada, Roche Global, Alexion, Apellis


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at